Taoka S, Padmakumar R, Lai M T, Liu H W, Banerjee R
Biochemistry Department, University of Nebraska, Lincoln 68583-0718.
J Biol Chem. 1994 Dec 16;269(50):31630-4.
Human methylmalonyl-CoA mutase is inhibited by ethylmalonyl-CoA, cyclopropylcarbonyl-CoA carboxylate, and methylenecyclopropylacetyl-CoA, which are substrate, intermediate, and product analogs, respectively. The mode of inhibition by each analog is reversible and mixed with respect to the substrate, methylmalonyl-CoA. This implies that the inhibitors are able to bind to both free enzyme and to the enzyme-substrate complex, although with affinities that are 4.5- to 10-fold different for the two species. The Ki1 for the cyclopropylcarbonyl-CoA carboxylate (0.26 +/- 0.07 mM), is 4-fold greater than the Km(app) measured for the substrate, methylmalonyl-CoA. Additionally, ethylmalonyl-CoA functions as an alternate substrate and is metabolized to methylsuccinyl-CoA. The human mutase is a homodimer that binds 1 mol of cobalamin per subunit. So, the observed mixed inhibition kinetics by substrate analogs is curious. Our finding that methylenecyclopropylacetyl-CoA, the causative agent of Jamaican "vomiting sickness," inhibits methylmalonyl-CoA mutase, while interesting, is probably not physiologically important because of the relatively high inhibition constants (Ki1 = 0.47 +/- 0.12 mM and Ki2 = 2 +/- 0.34 mM) observed with this compound.
人甲基丙二酰辅酶A变位酶分别被乙基丙二酰辅酶A、环丙羰基辅酶A羧酸盐和亚甲基环丙基乙酰辅酶A抑制,它们分别是底物类似物、中间体类似物和产物类似物。每种类似物的抑制模式都是可逆的,且相对于底物甲基丙二酰辅酶A而言是混合型的。这意味着抑制剂能够与游离酶和酶 - 底物复合物结合,尽管对这两种形式的亲和力相差4.5至10倍。环丙羰基辅酶A羧酸盐的Ki1(0.26±0.07 mM)比底物甲基丙二酰辅酶A的测得的表观Km大4倍。此外,乙基丙二酰辅酶A作为替代底物发挥作用,并被代谢为甲基琥珀酰辅酶A。人变位酶是一种同二聚体,每个亚基结合1摩尔钴胺素。因此,观察到的底物类似物的混合型抑制动力学很奇特。我们发现,牙买加“呕吐病”的致病因子亚甲基环丙基乙酰辅酶A抑制甲基丙二酰辅酶A变位酶,虽然这很有趣,但由于用该化合物观察到的抑制常数相对较高(Ki1 = 0.47±0.12 mM和Ki2 = 2±0.34 mM),它可能在生理上并不重要。